Navigation Links
Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Date:5/22/2013

hat contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of Type 2 diabetes. Valeritas' portfolio is headlined by the V-Go® disposable insulin delivery device, which is being commercialized and reimbursed in a specialty pharmaceutical model and is distributed through retail pharmacy.

V-Go meets an adult Type 2 diabetes patient's insulin needs by providing a treatment that is simple, convenient and easy to use. V-Go mimics the insulin pattern of the body (when used according to the Instructions for Patient Use) by providing a continuous preset basal rate of insulin over 24 hours and on-demand bolus dosing at mealtimes.

Valeritas' development portfolio also includes the h-Patch™ technology for the delivery of other compounds beyond insulin, the Mini-Ject™ Pre-Filled Needle-Free Delivery System, and the Micro-Trans™ Microneedle Transdermal Delivery Patch. These technologies, not commercially available, when combined with certain compounds, are designed to provide unique products that allow precise dosing in previously difficult to treat conditions.

In March 2011, Valeritas received EU CE Mark approval for V-Go. In November 2012, Valeritas was named Life Science Company of the year by the New Jersey Technology Council for its targeted mission and focus on the development of technology to improve the lives of people with Type 2 diabetes. Its Executive Management Team was further recognized for the ability to effectively develop and commercialize devices at high volumes. In addition, Valeritas received the 2012 Scrip Financing of the Year award for raising $150 million in Series C financing in September 2011.

Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, visit

SOURCE Valeritas, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
2. Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
3. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
4. Merck and Celebrity Chef Art Smith "Cook Up a Recipe" for Better Type 2 Diabetes Management
5. Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
6. New Interim Analysis From Observational Study Suggests That Delivery Of Insulin Via Valeritas V-Go Shows Promise In Improving Glycemic Control For Patients With Type 2 Diabetes
7. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
8. Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
9. Judge Nullifies Verdict in Diabetes Drug Case
10. The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small
11. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... discovery and development company, is delighted to announce that the ... awarded to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
(Date:1/22/2015)... WOODBRIDGE, ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics ... company with a focus on Omega-3 therapies for cardiovascular disease ... summary of the Company,s accomplishments in 2014 and its outlook ... Dear Fellow Shareholders, We would like ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... in Carotid Atherosclerosis, LEXINGTON, Mass., Oct. 24 ... its pivotal clinical trial (PROVIDENCE-1),studying the effect of ... peripheral arterial disease (PAD) will be,presented on November ... late breaker,Scientific Session at the American Heart Association,s ...
... Today the National Legal and Policy,Center (NLPC) asked ... for,International Development (USAID) to investigate the possibility that ... groups operating,needle exchange programs for drug users in ... activist George,Soros are recipients of these legally questionable ...
Cached Medicine Technology:ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 2ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting 3Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups 2
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... Mass. (PRWEB) January 22, 2015 EBSCO ... (AMA) are expanding their relationship in an effort to ... around the world. While EBSCO has long made AMA journals ... a sales agent for The JAMA Network. , ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... advanced non-small cell lung cancer appear to get no ... chemotherapy, researchers from the Dana-Farber Cancer Institute report. ... improve survival, but not in patients aged 65 and ...
... ANN ARBOR, Mich. Kidney cancer patients who had ... had their entire kidney removed, according to a new study ... After an average of five years, 25 percent of ... the tumor and a small margin of healthy tissue is ...
... Regenstrief Institute investigator Christopher Callahan, M.D., Cornelius and ... School of Medicine and director of the IU Center ... for Career Achievement and Contribution to Clinical and Translational ... Washington, D.C., April 18 to 20. Dr. Callahan, ...
... in young children and can lead to difficulties in ... mothers, depression has consistently been identified as one. Now ... levels of symptoms of depression might act in ways ... insights about maternal depression,s effects on nighttime parenting, and ...
... HealthDay Reporter , MONDAY, April 16 (HealthDay News) -- ... benefit on multiple sclerosis (MS), according a study by ... people worldwide. Some prior research has indicated that omega-3 ... benefit those with the disease, according to background information ...
... Gardner HealthDay Reporter , MONDAY, April 16 ... have dropped 30 percent since 2000 but still remain ... new statistics released by the U.S. Centers for Disease ... children died from unintentional injuries in the U.S. in ...
Cached Medicine News:Health News:Avastin No Benefit to Older Lung Cancer Patients: Study 2Health News:Avastin No Benefit to Older Lung Cancer Patients: Study 3Health News:Kidney cancer patients do better when whole kidney is not removed, U-M study shows 2Health News:Callahan honored for improving older adults' health in their doctors' offices 2Health News:Depressed moms' behavior may play role in infants' sleep problems 2Health News:Fish Oil Supplements Won't Help in Multiple Sclerosis: Study 2Health News:Death From Accidental Injuries Among Kids Drops 30%: CDC 2Health News:Death From Accidental Injuries Among Kids Drops 30%: CDC 3
Standard general retractor system. Fully-adjustable to maintain a low profile in any approach and any patient. Blades can be stacked on top of each other in the operative site....
These retractors, made of rugged Noryl® resin, are pre-sterilized and packaged singly in double peel-pouches for easy delivery to the sterile surgical field....
... abdominal surgery, the Alexis Wound Retractor ... wound from contamination. For open surgery, ... while minimizing the incision size. For ... instrumental in offering retraction and protection ...
HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin....
Medicine Products: